Valera Pharmaceuticals , Nasdaq: VLRX.X
Markets an implant for advanced prostate cancer and is developing other implants.
Industry: Health Care
First Day Return: +10.3%
Industry: Health Care
VLRX.X
Markets an implant for advanced prostate cancer and is developing other implants.
| IPO Data | |
|---|---|
| IPO File Date | 03/14/2005 |
| Offer Price | $9.00 |
| Price Range $10.00 - $12.00 | |
| Offer Shares (mm) | 3.8 |
| Deal Size ($mm) | $34 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 02/01/2006 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $34 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cranbury, NJ, United States |
| Founded | 1972 |
| Employees at IPO | 100 |
| Website www.hydromed.com | |
IPO News for Valera Pharmaceuticals
Valera Pharmaceuticals (VLRX.X) Performance
